精锋医疗构建了覆盖多科室的丰富管线。多孔系列MP1000 及升级款已获批多专科应用并实现商业化放 量，单孔系列SP1000 为国内首个覆盖三大外科的国产单孔机器人，支气管镜机器人CP1000 作为创新产 品实现肺部病变无创诊疗。2025 年起公司全面推进全球化战略，核心产品获欧盟CE 认证，已在14 个 境外司法管辖区取得注册批准，海外订单需求旺盛。 手术机器人赛道前景广阔，关注产业创新进展。受益于手术机器人行业技术革新、临床需求及政策红 利，全球及中国市场规模持续高速增长，其中中国单孔及自然腔道机器人细分赛道增速尤为突出。建议 积极关注国产手术机器人厂家的进口替代及出海进程。 风险提示：研发失败风险；商业化不及预期风险；地缘政治风险；政策超预期风险。 本周医药板块表现弱于整体市场，医药商业降幅居前。本周全部A 股下跌0.98%（总市值加权平均）， 沪深300 上涨0.08%，中小板指下跌3.78%，创业板指下跌0.09%，生物医药板块整体下跌3.31%，生物 医药板块表现弱于整体市场。分子板块来看，化学制药下跌3.20%，生物制品下跌2.50%，医疗服务下 跌4.15%，医疗器械下跌3.86%，医药商业下跌 ...

Core Insights - The article highlights the advancements of Shenzhen-based Jingfeng Medical in the field of surgical robotics, emphasizing its role in transforming China from a follower to a leader in high-end medical technology [1][5] Group 1: Technological Advancements - Jingfeng Medical has developed multiple surgical robot technologies, including multi-port, single-port, and natural orifice surgery robots, marking a significant achievement in the industry [1][2] - The company's multi-port laparoscopic surgical robot received CE certification in March, allowing it to enter the European medical device market, which has been dominated by foreign products [2][3] - Jingfeng Medical has independently mastered core technologies such as structural design, system control, motion algorithms, and artificial intelligence algorithms [2] Group 2: Clinical Achievements - The multi-port laparoscopic surgical robot has completed over 8,000 clinical surgeries globally, while the single-port version has surpassed 1,000 surgeries [2] - In November 2024, Jingfeng Medical successfully completed the world's first remote surgery using a single-arm single-port robot, demonstrating its innovative capabilities [2] Group 3: Global Expansion - Jingfeng Medical has established strategic partnerships with global leaders to expand into the European market, targeting over 30 key countries and regions for localized sales and support [3] - Since the start of 2025, the company has secured 25 commercial orders in nearly 20 countries within just seven months, indicating a rapid acceleration in its internationalization efforts [3] Group 4: Collaborative Innovation - The company has received regulatory approval for its bronchoscopic robot, CP1000, and has initiated clinical trials for laparoscopic and gynecological robots in Shenzhen [4] - Jingfeng Medical collaborates with local hospitals to create real-world testing environments for its products, enhancing innovation and data accumulation [4]

Core Insights - The article highlights the advancements of Shenzhen-based Jingfeng Medical in the field of surgical robotics, emphasizing its role in transforming China from a follower to a leader in high-end medical technology [1][5] Group 1: Technological Advancements - Jingfeng Medical has developed multiple surgical robot technologies, including multi-port, single-port, and natural orifice surgical robots, marking a significant achievement in the industry [1][2] - The company's multi-port laparoscopic surgical robot received CE certification in March, allowing it to enter the European medical device market, which has been dominated by foreign products [2][3] - Jingfeng Medical has independently mastered core technologies such as structural design, system control, motion algorithms, and AI algorithms [2] Group 2: Clinical Achievements - The multi-port laparoscopic surgical robot has completed over 8,000 clinical surgeries globally, while the single-port version has surpassed 1,000 surgeries [2] - In November 2024, Jingfeng Medical successfully completed the world's first remote surgery using a single-arm single-port robot, demonstrating its innovative capabilities [2] Group 3: Global Expansion - Jingfeng Medical has established strategic partnerships with global leaders to expand into the European market, targeting over 30 key countries and regions for localized sales and support [3] - The company has secured 25 commercial orders in nearly 20 countries within just seven months, indicating a rapid acceleration in its internationalization efforts [3] Group 4: Government and Industry Collaboration - The company has received regulatory approval for its bronchoscopic robot, CP1000, and has benefited from government support in creating real-world testing environments for new products [4] - Jingfeng Medical has initiated clinical trials for laparoscopic and gynecological robotic surgeries in collaboration with local hospitals, enhancing its application and demonstration of medical technologies [4]